If, when, and for how long anticoagulation should be administered in these 3 patients is the challenge in each case. Do you know your guidelines?
Payal Kohli, MD
Find out what you know and what you may need to brush up on in the primary and secondary prevention of CVD.
Which biomarker is most useful in what situation? Find out how one cardiologist makes these decisions. Do you concur?
The PCSK9 inhibitor class is here to stay. Find out what you know about the enzyme and how its inhibition is revolutionizing CHD prevention.
Click through our topline review of the key takeaways from this long-awaited update.
Patients who require dose adjustment when taking direct oral anticoagulants have not been well studied. This large study is a good start.
Quick Quiz: Which antiplatelet/antithrombin combination provides greatest efficacy with least risk for bleeding?
An incremental and tripartite approach to prevention, say researchers, will begin to shift AF disease distribution and decrease morbidity over time.
Which anticoagulant therapy has the greater absolute benefit in these complex patients?
Answers to these 5 questions about patient and pending procedure create a pathway to decisions about perioperative anticoagulation.